Chloroquine-primaquine therapeutic response and safety in patients with uncomplicated Plasmodium vivax malaria in the Colombian Amazon region.

IF 2.4 3区医学 Q3 INFECTIOUS DISEASES

Malaria Journal Pub Date : 2024-11-18 DOI:10.1186/s12936-024-05170-z

Paula Calderón-Ruiz, Gabriel Velez-Tobón, Sebastian Bolívar-Hernández, Luz Mila Murcia-Montaño, Alberto Tobón-Castaño

{"title":"Chloroquine-primaquine therapeutic response and safety in patients with uncomplicated Plasmodium vivax malaria in the Colombian Amazon region.","authors":"Paula Calderón-Ruiz, Gabriel Velez-Tobón, Sebastian Bolívar-Hernández, Luz Mila Murcia-Montaño, Alberto Tobón-Castaño","doi":"10.1186/s12936-024-05170-z","DOIUrl":null,"url":null,"abstract":"Background: In Colombia, published studies on the treatment of uncomplicated Plasmodium vivax malaria with chloroquine-primaquine are scarce. The aim of this study was to evaluate the therapeutic response to two treatment regimens at the 28-day follow-up and the occurrence of adverse events in patients with P. vivax malaria.Methods: A quasi-experimental clinical trial was conducted at 3 sites in the Department of Amazonas. Patients received supervised or unsupervised anti-malarial treatment (chloroquine plus primaquine), and the primary effectiveness endpoint was the clinical and parasitological response. Safety was assessed through adverse event surveillance.Results: A total of 103 patients were included: 53 in the 7-day primaquine group (Group I) and 50 in the group receiving primaquine for 14 days (Group II). Among the patients in group I, an adequate treatment response of 100% and 89.5% was found in patients who received supervised and unsupervised treatment, respectively. In Group II, adequate responses of 100% and 95% were reported for patients who received supervised and unsupervised treatment, respectively. No adverse events were detected.Conclusions: The response to combined treatment with chloroquine plus primaquine continues to be adequate for treating P. vivax malaria in the Colombian Amazon region; however, a response to unsupervised treatment in the region is recommended.","PeriodicalId":18317,"journal":{"name":"Malaria Journal","volume":"23 1","pages":"348"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaria Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12936-024-05170-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In Colombia, published studies on the treatment of uncomplicated Plasmodium vivax malaria with chloroquine-primaquine are scarce. The aim of this study was to evaluate the therapeutic response to two treatment regimens at the 28-day follow-up and the occurrence of adverse events in patients with P. vivax malaria.

Methods: A quasi-experimental clinical trial was conducted at 3 sites in the Department of Amazonas. Patients received supervised or unsupervised anti-malarial treatment (chloroquine plus primaquine), and the primary effectiveness endpoint was the clinical and parasitological response. Safety was assessed through adverse event surveillance.

Results: A total of 103 patients were included: 53 in the 7-day primaquine group (Group I) and 50 in the group receiving primaquine for 14 days (Group II). Among the patients in group I, an adequate treatment response of 100% and 89.5% was found in patients who received supervised and unsupervised treatment, respectively. In Group II, adequate responses of 100% and 95% were reported for patients who received supervised and unsupervised treatment, respectively. No adverse events were detected.

Conclusions: The response to combined treatment with chloroquine plus primaquine continues to be adequate for treating P. vivax malaria in the Colombian Amazon region; however, a response to unsupervised treatment in the region is recommended.

查看原文本刊更多论文

哥伦比亚亚马逊地区无并发症间日疟原虫疟疾患者对氯喹-伯氨喹的治疗反应和安全性。

背景：在哥伦比亚，有关氯喹-伯氨喹治疗无并发症间日疟原虫疟疾的公开研究很少。本研究旨在评估两种治疗方案在 28 天随访期间的治疗反应以及间日疟原虫疟疾患者不良反应的发生情况：在亚马孙省的 3 个地点开展了一项准实验性临床试验。患者接受有监督或无监督的抗疟治疗（氯喹加伯氨喹），主要疗效终点是临床和寄生虫学反应。安全性通过不良事件监测进行评估：共纳入 103 名患者：结果：共纳入103名患者：53名患者接受为期7天的伯氨喹治疗（I组），50名患者接受为期14天的伯氨喹治疗（II组）。在 I 组患者中，接受监督治疗和非监督治疗的患者的充分治疗反应分别为 100%和 89.5%。在第二组中，接受监督治疗和未接受监督治疗的患者的充分治疗反应分别为 100%和 95%。未发现任何不良反应：结论：在哥伦比亚亚马逊地区，氯喹加伯氨喹联合治疗的反应仍足以治疗间日疟原虫性疟疾；不过，建议该地区的患者接受无监督治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Malaria Journal 医学-寄生虫学

CiteScore

5.10

自引率

23.30%

发文量

334

审稿时长

2-4 weeks

期刊介绍： Malaria Journal is aimed at the scientific community interested in malaria in its broadest sense. It is the only journal that publishes exclusively articles on malaria and, as such, it aims to bring together knowledge from the different specialities involved in this very broad discipline, from the bench to the bedside and to the field.